Research programme: bispecific antibodies - Amgen

Drug Profile

Research programme: bispecific antibodies - Amgen

Alternative Names: AMG 596; AMG CDH19X; Anti-MSLN/CD3 BiTE® antibody; DLL3 BiTE®

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacokinetics data from a preclinical study in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Pharmacokinetics data from a preclinical study presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Jan 2017 Preclinical trials in Solid tumours in Germany and USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top